Ironwood beats Q3 earnings estimates and raises 2026 outlook
FROM THE WIRE · FINANCE.YAHOO.COM
Ironwood Pharmaceuticals IRWD reported adjusted earnings of 36 cents per share for the third quarter of 2026, surpassing the Zacks Consensus Estimate of 30 cents. The company had reported adjusted earnings of 24 cents per share in the year-ago quarter. Total revenues in the…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishEarnings beat and raised guidance at a small biotech, though revenue missed estimates.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Ironwood reported Q3 2026 adjusted EPS of 36 cents.
- 02Total revenue was $133 million, below the $149 million estimate.
- 03Shares rose 6.9% following the results and raised 2026 outlook.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Ironwood Pharmaceuticals, Inc.4.42 USD+0.35%today +9.56%Positive AbbVie Inc.290.53 USD-0.20%today +0.79%Neutral Collegium Pharmaceutical, Inc.24.57 USD+0.03%today -2.33%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets